Are Biotech Stocks Due for a Correction in 2020?

Are Biotech Stocks Due for a Correction in 2020?

Source: 
Motley Fool
snippet: 

As good a year as 2019 was for the markets, it was an even better one for biotech. While the S&P 500 rose 30% during the year, many biotech stocks soared much higher. Axsome Therapeutics (NASDAQ: AXSM) skyrocketed more than 3,500% in 2019, dwarfing Seattle Genetics (NASDAQ: SGEN), which "only" doubled, while Vertex Pharmaceuticals' (NASDAQ: VRTX) 32% increase looked downright ordinary.